Julia Dudnik

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee et al. · Journal of Clinical Oncology · 2024 · 142 citations · Full text

Medicine, Oncology, Pharmacology +14

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

Luis Paz‐Ares, Óscar Juan, Giannis Mountzios et al. · Journal of Clinical Oncology · 2024 · 115 citations · Full text

Medicine, Oncology, Pharmacology +17

Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial

James Chih‐Hsin Yang, Baohui Han, Emmanuel de la Mora Jimenez et al. · Journal of Thoracic Oncology · 2023 · 51 citations · Full text

Medicine, Oncology, Pharmacology +17

Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases

Iris M. Goldstein, Laila C. Roisman, Shoshana Keren-Rosenberg et al. · Neuro-Oncology Advances · 2020 · 27 citations · Full text

Medicine, Oncology, Pharmacology +17

The impact of osimertinib’ line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance

Vered Fuchs, Laila C. Roisman, Waleed Kian et al. · Lung Cancer · 2021 · 26 citations

Medicine, Molecular Biology, Pharmacology +17